How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

British Journal of Pharmacology

Volumn 163, Issue 4, 2011, Pages 675-693

  Laverty, H G ^a   Benson, C ^b   Cartwright, E J ^c   Cross, M J ^a   Garland, C ^d   Hammond, T ^e   Holloway, C ^d   McMahon, N ^f   Milligan, J ^e   Park, B K ^a   Pirmohamed, M ^a   Pollard, C ^e   Radford, J ^c   Roome, N ^g   Sager, P ^h   Singh, S ⁱ   Suter, T ^j   Suter, W ^k   Trafford, A ^c   Volders, P G A ^l   Wallis, R ^m   Weaver, R ⁿ   York, M ^f   Valentin, J P ^e   more..

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

^g SANOFI   (France)

^h Cardiac Safety Research Consortium Scientific Oversight Committee   (United States)

ⁱ MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^j BERN UNIVERSITY HOSPITAL   (Switzerland)

^k Novartis Pharma AG   (Switzerland)

^l MAASTRICHT UNIVERSITY   (Netherlands)

^m PFIZER INC   (United States)

ⁿ Servier Research and Development Ltd   (United Kingdom)

more..

Author keywords

adverse drug reaction; adverse event; cardiovascular safety liabilities; drug attrition; medicines; patient safety

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT; FENFLURAMINE; NORFENFLURAMINE; PERGOLIDE; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG RESEARCH; DRUG SAFETY; EMBOLISM; ENDOCARDIUM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; NONHUMAN; PERICARDIAL DISEASE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SHORT QT INTERVAL; THROMBOSIS; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASCULITIS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 79958021542     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01255.x     Document Type: Review

References (78)

1. Anon (2010a). Adverse Event Reporting System (AERS)-U.S. Food and Drug Administration-U.S. Department of Health & Human Services. (accessed on 1st July 2010).
2. Anon (2010b). Top Institute Pharma. (accessed on 22nd November 2010).
3. Anon (2010c). Cardiac Safety Research Consortium. (accessed on 22nd November 2010).
4. Anon (2010d). Critical Path Institute's Predictive Safety Testing Consortium. (accessed on 22nd November 2010).
5. Anon (2010e). Innovative Medicines Initiative. (accessed on 22nd November 2010).
6. Anon (2010f). The Health and Environmental Sciences Institute. (accessed on 22nd November 2010).
7. Anon (2010g). Stem Cells for Safer Medicines (SC4SM). (accessed on 31th March 2011).
8. Aronov AM, (2008). Ligand structural aspects of hERG channel blockade. Curr Top Med Chem 8: 1113-1127.
9. Bass A, Valentin JP, Fossa AA, Volders PG, (2007). Points to consider emerging from a mini-workshop on cardiac safety: assessing torsades de pointes liability. J Pharmacol Toxicol Methods 56: 91-94. (Pubitemid 47375128)
10. Bass AS, Darpo B, Breidenbach A, Bruse K, Feldman HS, Garnes D, et al,. (2008). International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes. Br J Pharmacol 154: 1491-1501.
11. Baubuin L, Jaffee AS, (2005). Troponin; the biomarker of choice for the detection of cardiac injury. CMAJ 173: 1191-1202.
12. Belhani D, Frassati D, Mégard R, Tsibiribi P, Bui-Xuan B, Tabib A, et al,. (2006). Cardiac lesions induced by neuroleptic drugs in the rabbit. Exp Toxicol Pathol 57: 207-212. (Pubitemid 43061191)
13. Bers DM, (2002). Cardiac excitation-contraction coupling. Nature 415: 198-205. (Pubitemid 34059525)
14. Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, et al,. (2007). Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 28: 1904-1909. (Pubitemid 47236658)
15. Brott D, Jones H, Gould S, Valentin JP, Evans G, Richardson RJ, et al,. (2005). Current status and future directions for diagnostic markers of drug-induced vascular injury. Cancer Biomark 1: 15-28.
16. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL, (2006). National surveillance of emergency department visits for outpatient adverse drug effects. JAMA 296: 1858-1866. (Pubitemid 44596195)
17. Car B, (2006). Enabling technologies in reducing drug attrition due to safety failures. Am Drug Discov 1: 53-56.
18. Cavero I, (2010). Cardiovascular system assessment best practices: a Safety Pharmacology Society meeting. Expert Opin Drug Saf 9: 855-866.
19. Chalmers J, Arima H, (2010). Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol 55: 340-347.
20. Chekmarev DS, Kholodovych V, Balakin KV, Ivanenkov Y, Ekins S, Welsh WJ, (2008). Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol 21: 1304-1314. (Pubitemid 351967396)
21. Cheng H, Force T, (2010). Molecular mechanisms of cardiovascular toxicity of targeted cancer Therapeutics. Circ Res 106: 21-34.
22. Chun HJ, Narula J, Hofstra L, Wu JC, (2008). Intracellular and extracellular targets of molecular imaging in the myocardium. Nat Clin Pract Cardiovasc Med 5 (Suppl. 2): S33-S41.
23. Darpo B, (2010). The thorough QT study four years after the implementation of the ICH E14 guidance. Br J Pharmacol 159: 49-57.
24. De Keulenaer GW, Doggen K, Lemmens K, (2010). The vulnerability of the heart as a pluricellular paracrine organ lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106: 35-46.
25. Detweiler DK, (1983). Electrocardiographic monitoring in toxicological studies: principles and interpretations. Adv Exp Med Biol 161: 579-607.
26. Frid AA, Matthews EJ, (2010). Prediction of drug-related cardiac adverse effects in humans-B: use of QSAR programs for early detection of drug-induced cardiac toxicities. Regul Toxicol Pharmacol 56: 276-289.
27. Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E, (2001). Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets-1960 to 1999. Drug Inf J 35: 293-317. (Pubitemid 32198581)
28. Gallacher DJ, Van de Water A, van der Linde H, Hermans AN, Lu HR, Towart R, et al,. (2007). In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome. Cardiovasc Res 76: 247-256. (Pubitemid 350198588)
29. Gavaghan CL, Arnby CH, Blomberg N, Strandlund G, Boyer S, (2007). Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J Comput Aided Mol Des 21: 189-206. (Pubitemid 46510843)
30. Gussak I, Litwin J, Kleiman R, Grisanti S, Morganroth J, (2004). Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development. J Electrocardiol 37: 19-24. (Pubitemid 38168825)
31. Guth BD, Bass AS, Briscoe R, Chivers S, Markert M, Siegl PKS, et al,. (2009). Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies. J Pharmacol Toxicol Methods 60: 107-116.
32. Hanton G, Eder V, Rochefort G, Bonnet P, Hyvelin JM, (2008). Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology. Expert Opin Drug Metab Toxicol 4: 681-696. (Pubitemid 352003193)
33. Hoffmann P, Warner B, (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 53: 87-105.
34. Holmes K, Roberts OL, Thomas AM, Cross MJ, (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012. (Pubitemid 47354167)
35. Joy TR, Hegele RA, (2008). The failure of torcetrapib: what have we learned? Br J Pharmacol 154: 1379-1381.
36. Kennedy T, (1997). Managing the drug discovery/development interface. Drug Discov Devel 2: 436-444. (Pubitemid 27387353)
37. Kola I, Landis J, (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715. (Pubitemid 39173511)
38. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, et al,. (2003). Predicting ADME properties and side effects: the bioprint approach. Curr Opin Drug Discov Devel 6: 470-480. (Pubitemid 36975350)
39. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH, (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA 287: 2215-2220. (Pubitemid 34441937)
40. Leeson D, Springthorpe B, (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev 6: 881-890. (Pubitemid 350042396)
41. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913. (Pubitemid 35472129)
42. Louden C, Brott D, Katein A, Kelly T, Gould S, Jones H, et al,. (2006). Biomarkers and mechanisms of drug-induced vascular injury in non-rodents. Toxicol Pathol 34: 19-26. (Pubitemid 43323256)
43. McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM, Kim RB, et al,. (2009). The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 54: 63-71.
44. Munos B, (2009). Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Dis 8: 959-968.
45. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al,. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32: 56-67.
46. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al,. for the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators (2009). A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 361: 2538-2547.
47. Park BK, (2008). Medical Research Council (MRC) Centre for Drug Safety science. (accessed 9th May 2010).
48. Partridge CR, Johnson CD, Ramos KS, (2005). In vitro models to evaluate acute and chronic injury to the heart and vascular systems. Toxicol In Vitro 19: 631-644. (Pubitemid 40719538)
49. Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JMC, et al,. (2010). Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 55: 567-574.
50. Peng X, Pentassuglia L, Sawyer DB, (2010). Emerging anticancer therapeutic targets and the cardiovascular system. Is there cause for concern? Circ Res 106: 1022-1034.
51. Pettit SD, Berridge B, Sarazan RD, (2010). A call for more integrated cardiovascular safety assessment. J Pharmacol Toxicol Methods 61: 1-2.
52. Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, et al,.; CSRC/HESI Writing Group (2009). Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 158: 317-326.
53. Pollard CE, Abi-Gerges N, Bridgland-Taylor MH, Easter A, Harmer A, Hammond TG, et al,. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
54. Price DA, Blagg J, Jones L, Greene N, Wager T, (2009). Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol 5: 921-931.
55. Pugsley MK, Authier S, Curtis MJ, (2008). Principles of safety pharmacology. Br J Pharmacol 154: 1382-1399.
56. Pugsley MK, Authier S, Towart R, Gallacher DJ, Curtis MJ, (2009). Beyond the safety assessment of drug-mediated changes in the QT interval. what's next? J Pharmacol Toxicol Methods 60: 24-27.
57. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al,. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45. (Pubitemid 36351620)
58. Redfern WS, Ewart L, Hammond TG, Bialecki R, Kinter L, Lindgren S, et al,. (2010). Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114: 1081.
59. Reinhold T, Berghöfer A, Willich SN, (2010). Is the determination of biomarkers worth its price? Review of the literature taking brain natriuretic peptides (BNP) as an example. Herz 35: 1-10.
60. Reiss AB, Anwar F, Chan ES, Anwar K, (2009). Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk. J Investig Med 57: 695-702.
61. Roth BL, (2007). Drugs and valvular heart disease. N Engl J Med 356: 6-9.
62. Shah RR, (2006). Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7: 889-908. (Pubitemid 44446737)
63. Shah RR, (2010). Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspective. Br J Pharmacol 159: 58-69.
64. Sibille M, Deigat N, Janin A, Kirkesseli S, Durand DV, (1998). Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol 54: 13-20. (Pubitemid 28189393)
65. Stevens JL, Baker TK, (2009). The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 14: 162-167.
66. Stummann TC, Beilmann M, Duker G, Dumotier B, Fredriksson JM, Jones RL, et al,. (2009). Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for drug-induced cardiotoxicity. Cardiovasc Toxicol 9: 107-125.
67. Taylor GL, Patel B, Sullivan AT, (2007). Evaluation of blood flow parameters in addition to blood pressure and electrocardiogram in the conscious telemetered beagle dog. J Pharmacol Toxicol Methods 56: 212-217. (Pubitemid 47375126)
68. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al,.; the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care (2010). Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 31: 2197-2204.
69. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al,. (2010). MiR423-5p as a circulating biomarker for heart failure. Circ Res 106: 1035-1039.
70. Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M, et al,. (2004). Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 199: 52-60. (Pubitemid 39099455)
71. Valentin JP, (2010). Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol 159: 5-11.
72. Valentin JP, Bialecki R, Ewart L, Hammond TG, Leishman D, Lindgren S, et al,. (2009a). A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 60: 152-158.
73. Valentin JP, Keisu M, Hammond TG, (2009b). Predicting human adverse drug reactions from non-clinical safety studies. In:, Gad SC, (ed.). Clinical Trials Handbook. John Wiley & Sons, Inc: Hoboken, NJ, pp. 87-113.
74. Valentin JP, Pollard CE, Lainee P, Hammond T, (2010). Value of nonclinical repolarization assays in supporting the discovery and development of safer medicines. Br J Pharmacol 159: 25-33.
75. Vik T, Pollard C, Sager P, (2008). Early clinical development: evaluation of drug-induced torsades de pointes risk. Pharmacol Ther 119: 210-214.
76. Wallis RM, (2010). Integrated risk assessment and predictive value to humans of non-clinical repolarisation assays. Br J Pharmacol 159: 115-121.
77. Whitebread S, Hamon J, Bojanic D, Urban L, (2005). Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 10: 1421-1433. (Pubitemid 41483871)
78. Zuppinger C, Suter TM, (2010). Cancer therapy-associated cardiotoxicity and signaling in the myocardium. J Cardiovasc Pharmacol 56: 141-146.